Planning
5 pages in this section, most recently updated September 4, 2026.
- 01
Pregnancy planning on a GLP-1: the semaglutide wash-out, the tirzepatide contraception warning, and what to do if you are already pregnant
The Wegovy and Ozempic labels say to stop at least 2 months before a planned pregnancy. The Zepbound and Mounjaro labels say oral contraceptives may be less effective and to add a barrier method for 4 weeks after starting and after each increase. The exact label language, what it rests on, breastfeeding, and the registries.
Updated September 4, 2026
- 02
Switching between GLP-1s: what the labels and trials support, and what nobody has studied
Semaglutide to tirzepatide, Ozempic to Wegovy, brand to compounded and back: the labels contain no switching instructions, and only one trial compares the two drugs head to head. What SURMOUNT-5 and SURPASS-2 show, how prescribers reason about the starting dose after a switch, and the questions to settle before the first new injection.
Updated September 4, 2026
- 03
Stopping a GLP-1 and keeping the weight off: what SURMOUNT-4, STEP 4 and the STEP 1 extension actually measured
The three trials that randomised or followed people off semaglutide and tirzepatide give the clearest numbers in the whole field: most of the weight returns within a year. What each trial did, what it did not test, and a maintenance plan built from the evidence that exists.
Updated September 4, 2026
- 04
Appealing a GLP-1 coverage denial: an overview of prior authorisation, the label indications that matter, and the appeal rights you have
Most GLP-1 denials come down to one of four things: the drug is excluded, the indication does not match the label, the prior authorisation criteria were not documented, or a step-therapy rule was not met. How to read the denial letter, what the labels say your prescriber can certify, and the internal and external appeal process under federal rules.
Updated September 4, 2026
- 05
Talking to your prescriber: a checklist for the first visit, every follow-up, and the conversations people avoid
What to bring, what to report, and what to ask at each stage of GLP-1 therapy, organised so a ten-minute appointment covers what the labels say matters: history the label screens for, the escalation options, warning signs, procedures, pregnancy, and the questions that decide whether a switch or a stop goes well.
Updated September 4, 2026